MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
65.92
-0.15
-0.23%
After Hours: 66.00 +0.08 +0.12% 19:57 09/25 EDT
OPEN
66.50
PREV CLOSE
66.07
HIGH
67.44
LOW
65.40
VOLUME
1.62M
TURNOVER
--
52 WEEK HIGH
95.49
52 WEEK LOW
30.71
MARKET CAP
9.31B
P/E (TTM)
-29.4246
1D
5D
1M
3M
1Y
5Y
1D
Arrowhead’s Plozasiran Trial Completion Marks a Key Catalyst in the Triglyceride Market
TipRanks · 2d ago
Arrowhead Pharmaceuticals Price Target Announced at $74.00/Share by Goldman Sachs
Dow Jones · 3d ago
Goldman Sachs Reinstates Neutral on Arrowhead Pharma, Announces $74 Price Target
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Arrowhead Pharmaceuticals (ARWR)
TipRanks · 3d ago
Nasdaq 100 Slips, 10-Year Yields Hit 19-Year Highs: Stock Market Today
Benzinga · 4d ago
These 'Moonshot' Biotech Stocks Could Break Out, Morgan Stanley Says. What Must Go Right.
Barron‘s · 4d ago
Arrowhead Pharmaceuticals (ARWR) Receives a Rating Update from a Top Analyst
TipRanks · 6d ago
Weekly Report: what happened at ARWR last week (0914-0918)?
Weekly Report · 6d ago
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.